Latham & Watkins Advises Blackstone Life Sciences on US$750 Million R&D Funding Agreement, the Largest R&D Funding Agreement in 2026

Blackstone Life Sciences will provide $750M to Johnson & Johnson for Phase 3 trials of OLN324, a retinal disease therapy. The funding follows the expected acquisition of Ollin Biosciences. Latham & Watkins advised Blackstone on the deal.

Original reporting
Published Nov 18, 2026, 2:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 6:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Latham & Watkins Advises Blackstone Life Sciences on US$750 Million R&D Funding Agreement, the Largest R&D Funding Agreement in 2026 — source image
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

A $750 million R&D funding agreement is a concrete financing catalyst for J&J’s OLN324 Phase 3 program, potentially lowering development funding risk and supporting pipeline continuity through late-stage execution.

02

Market read

Traders may reassess J&J’s near-term pipeline financing risk and the perceived momentum of its late-stage retinal program.

03

What to watch

Key details like economics (repayment, royalties, dilution, covenants) are not provided here, which could materially affect net value to J&J beyond headline funding size.

Relevance 7/10Novelty 7/10Timing: today, as the deal announcement is newly disclosed

Background

The piece is a law-firm transaction note describing Blackstone Life Sciences providing development funding to Johnson & Johnson for Phase 3 of OLN324 after the expected closing of Blackstone’s acquisition of Ollin Biosciences.

Company-level read

Ticker impact

$JNJBullishMedium confidence
Context

Blackstone Life Sciences funds provide $750 million for Johnson & Johnson to finance Phase 3 development of OLN324 for retinal vascular diseases.

Expected impact

Likely modest positive bias as investors price lower funding risk and improved probability of progressing OLN324 through Phase 3.

Evidence & confidence

The article discloses a large, specific $750 million R&D funding arrangement tied to J&J’s Phase 3 program, which is directionally supportive, though it is not a direct earnings or regulatory milestone.

Market effects

Highlights continued availability of structured healthcare finance for late-stage biotech-style development within large pharma pipelines.

Limited direct regional market linkage; primarily US healthcare capital markets sentiment.

Moderate, as it reflects cross-border style healthcare finance structures that can influence global biotech/pharma funding expectations.

Counterpoint

The funding may not change clinical or regulatory outcomes, so equity reaction could be muted if investors view it as financial engineering rather than a science catalyst.

Key entities

  • Johnson & Johnson

    Receives $750 million in development funding to support Phase 3 clinical development of OLN324.

  • Blackstone Life Sciences

    Provides the $750 million development funding via funds it manages.

  • Ollin Biosciences, Inc.

    Acquisition by Blackstone is referenced as expected to close before the funding supports OLN324 Phase 3.

  • OLN324

    Investigational therapy for serious retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.

Related articles

$JNJMed

RSV Vaccine Cuts Lower Respiratory Disease in Older Adults

A phase 3 trial showed Johnson & Johnson's RSV vaccine was 73% effective in preventing lower respiratory tract disease and 68% effective against acute respiratory infection in adults 60+. The vaccine had more local adverse reactions but similar serious adverse event rates compared to placebo. The study was terminated early for strategic reasons, with efficacy maintained across age groups. Johnson & Johnson funded the study, and several authors have ties to the company.

$JNJMedAI 8/10

J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding

Johnson & Johnson (JNJ) agreed to acquire Ollin Biosciences for $2.2B, gaining OLN324, a late-stage eye drug that could compete with Roche's Vabysmo. OLN324 showed promising results in Phase 1b trials for AMD and DME. Blackstone Life Sciences will fund up to $750M for OLN324's development. The deal includes up to $1.1B in milestone payments. JNJ expects to close the transaction by year-end.

$JNJMedAI 9/10

Johnson & Johnson Stocks Edge Higher on $2.2 Billion Ollin Eye Deal

Johnson & Johnson (JNJ) shares rose to $286.06 after agreeing to acquire Ollin Biosciences for $2.2 billion upfront, with potential milestone payments up to $1.125 billion. Ollin, a clinical-stage company, develops treatments for serious eye diseases, including OLN324 for retinal diseases. Blackstone Life Sciences will fund OLN324's Phase 3 development in exchange for milestone payments and royalties. The deal adds to J&J's pipeline without significantly impacting its balance sheet.